Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.

The American journal of geriatric pharmacotherapy - 1 Aug 2010

Guay David R P

Abstract excerpt

BACKGROUND: Few drugs are available for the management of hyperkinetic movement disorders such as the dystonias, choreas, dyskinesias, and tics. Those that are available (primarily neuroleptics) are associated with a wide range of potentially serious adverse effects, including induction of tardiv...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dopamine
Share to Drug Interactions
Share to Huntington Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperkinesis

Share to Movement Disorders

Share to Parkinson Disease, Secondary

Share to Serotonin

Share to Vesicular Monoamine Transport Proteins

Source

Identifiers

PMID: 20869622
DOI: 10.1016/j.amjopharm.2010.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20869622-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.PMID 20869622Read ↗

New Directions in Therapeutics for Huntington DiseaseSemantic proximity Read ↗

Understanding Drug-Induced Movement Disorders: Causes, Symptoms, and TreatmentSemantic proximity Read ↗

Analysis of CYP2D6 genotype and response to tetrabenazine.Semantic proximity Read ↗

Systematic Evaluation of Adverse Drug Reactions Associated with Benzodiazepine Utilization: A Comprehensive ReviewSemantic proximity Read ↗

Dyskinesia after Levetiracetam Therapy: A Case ReportSemantic proximity Read ↗

Case Report of Management of Severe Tardive Dyskinesia Induced by an Atypical Antipsychotic in a Schizophrenic PatientSemantic proximity Read ↗

KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson’s diseaseSemantic proximity Read ↗

Neurochemical and Neurophysiological Effects of Intravenous Administration of <i>N,N</i> -Dimethyltryptamine in RatsSemantic proximity Read ↗

Agmatine interaction with imidazoline receptor inhibits manifestation of depression-like behavior in 3-Nitropropionic acid-induced Huntington's disease-like phenotype in rats.Semantic proximity Read ↗

Comparative Molecular Docking and Toxicity Profiling of Buspirone and Tandospirone Targeting the HTR1A ReceptorSemantic proximity Read ↗

Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction.Semantic proximity Read ↗

Movement disorders and alcohol misuse.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.